News Archives - Page 78 of 722

MondayAug 26, 2024 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market

Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration with the National Research Council of Canada (“NRC”) The study’s objective was to examine the molecular properties of semaglutide, processed with its patented DehydraTECH(TM) technology, comparing it to Rybelsus(R), the commercially available alternative Lexaria’s DehydraTECH demonstrated that semaglutide can be efficiently released in a simulated gastric fluid environment, without the use of salcaprozate sodium (“SNAC”) ingredient chemistry This milestone moves the company closer to the diabetes treatment market, projected to hit $153.98 billion in value by 2032 Lexaria Bioscience (NASDAQ:…

MondayAug 26, 2024 11:15 am

SuperCom Ltd. (NASDAQ: SPCB) Reports Q2, H1 Earnings Growth, Record Profit

Electronic monitoring solutions company SuperCom Ltd. provides a suite of products and services to justice system officials worldwide, promoting public safety through the secure tracking of individuals who require supervision SuperCom’s PureSecurity technology has the ability to serve a wide variety of tracking purposes but is specifically targeting electronic monitoring of offenders, including domestic violence cases, drug rehabilitation services, and probation orders The company recently reported its second quarter and first half financial results, noting growth across multiple metrics, including record profits following a 65.2 percent surge in gross profit and 20.4 percent growth in gross profit margin SuperCom’s EBITDA…

MondayAug 26, 2024 10:30 am

ECGI Holdings Inc. (ECGI) Following Proven Path from High-End Equestrian Market to Full-Scope Luxury Market

Many renowned luxury brands – fashion houses and watchmakers – honor their equestrian roots and the strong relationship with horses, from Rolex and Longines to Burberry, Gucci, Hermès, and Ralph Lauren The companies, which have successfully remained in operation for decades and continue to be influenced by equestrian elements, underscore the proven potential of the luxury equestrian market to build large-scale luxury players Beyond an equestrian influence, leading fashion houses emphasize and embody quality, unmatched craftsmanship, and innovation, qualities that ECGI Holdings and its subsidiary Pacific Saddlery have adopted A diversified holding company, ECGI Holdings intends to cater to the…

MondayAug 26, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces Encouraging Clinical Trial Results, IP Portfolio Enhancement

The company has released key corporate and business updates and Q2 2024 financial results Clinical trials for both Alzheimer’s and Parkinson’s studies yielded encouraging data for lead compound buntanetap Buntanetap in combination with GLP-1 agonist dulaglutide Trulicity(R) showed increased potential to synergistically enhance cognition The company has obtained a patent and begun manufacturing of a new crystalline form of buntanetap, with improved properties Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), offered key business updates and announced financial results for the second quarter…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer's Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer's Disease, and INM-901-treated Alzheimer's Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

FridayAug 23, 2024 9:00 am

SenesTech Inc. (NASDAQ: SNES) Building Quickly Across Multiple Channels

SenesTech recently released Q2 2024 financial results and hosted a conference call, confirming 50% revenue growth in the just-ended quarter, and year-to-date growth 62% During the call, Joel Fruendt, President and CEO, discussed the company’s progress and accomplishments, including the successful efficacy trial of Evolve to support the product’s approval in certain states and international jurisdictions Fruendt also discussed the company’s commercialization plans, centered around the pivot from the reliance on direct sales to the use of distributors So far, SenesTech has onboarded three of the top five national multi-location distributors and is in the process of bringing the fourth…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

WednesdayAug 21, 2024 9:45 am

National Investment Banking Association 150th Investment Conference Comes to Ft. Lauderdale, Florida

The National Investment Banking Association (“NIBA”) invites the micro-cap and small-cap investment community to its 150th investment conference. The event will be held on September 4-5, 2024, at the Westin Fort Lauderdale Beach Resort, Ft. Lauderdale, Florida. Since 1982, The National Investment Banking Association has been a not-for-profit association for the micro-cap and small-cap investment community and has hosted 149 investment conferences featuring public and private micro-cap and small-cap companies seeking access to the financial industry. NIBA’s member firms have a 40 year track record of successfully completing thousands of transactions totaling over $80 billion in new capital for emerging…

WednesdayAug 21, 2024 9:00 am

D-Wave Quantum Inc. (NYSE: QBTS) Reports Strong Q2 2024 Results

The company reported a 28% increase in revenue, a 6% rise in bookings, a 97% improvement in GAAP gross profit and a 444% increase in cash, for the second quarter of 2024, on a year over year basis D-Wave's CEO, Dr. Alan Baratz, summarized the company's ongoing strategic direction and provided an expansive list of achievements Highlights mentioned include a quantum AI product development roadmap extending D-Wave’s Leap(TM) quantum cloud service, an expanded partnership with Zapata AI, new customer hybrid quantum applications, and more D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the first…

Site Search

Company Search

Category: News